Surgery for gastrointestinal malignant melanoma: Experience from surgical training center

Thawatchai Akaraviputh, Satida Arunakul, Varut Lohsiriwat, Cherdsak Iramaneerat, Atthaphorn Trakarnsanga

Thawatchai Akaraviputh, Satida Arunakul, Varut Lohsiriwat, Cherdsak Iramaneerat, Atthaphorn Trakarnsanga, Division of General Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

Author contributions: Akaraviputh T originated the idea and drafted the manuscript; Arunakul S collected the data and conducted statistical analyses; Lohsiriwat V wrote part of the manuscript; Iramaneerat C critically reviewed and edited the manuscript; Trakarnsanga A gave comment and wrote part of the manuscript.

Correspondence to: Dr. Thawatchai Akaraviputh, MD, Endo-Laparoscopic Surgery Unit, Division of General Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. sitak@mahidol.ac.th

Telephone: +66-2-4198005-6 Fax: +66-2-4121370

Received: August 24, 2009 Revised: November 30, 2009 Accepted: December 7, 2009 Published online: February 14, 2010

Abstract

AIM: To characterize clinical features, surgery, outcome, and survival of malignant melanoma (MM) of the gastrointestinal (GI) tract in a surgical training center in Bangkok, Thailand.

METHODS: A retrospective review was performed for all patients with MM of the GI tract treated at our institution between 1997 and 2007.

RESULTS: Fourteen patients had GI involvement either in a metastatic form or as a primary melanoma. Thirteen patients with sufficient data were reviewed. The median age of the patients was 66 years (range: 32-87 years). Ten patients were female and three were male. Seven patients had primary melanomas of the anal canal, stomach and the sigmoid colon (5, 1 and 1 cases, respectively). Seven patients underwent curative resections: three abdominoperineal resections, two wide local excisions, one total gastrectomy and one sigmoidectomy. Six patients had distant metastatic lesions at the time of diagnosis, which made curative resection an inappropriate choice. Patients who underwent curative resection exhibited a longer mean survival time (29.7 mo, range: 10-96 mo) than did patients in the palliative group (4.8 mo, P = 0.0006).

CONCLUSION: GI MM had an unfavorable prognosis, except in patients who underwent curative resection (53.8% of cases), who had a mean survival of 29.7 mo.

© 2010 Baishideng. All rights reserved.

Key words: Melanoma; Gastrointestinal tract; Neoplasm metastasis

Peer reviewers: Nadia Peparini, MD, PhD, Department of General Surgery “Francesco Durante”, La Sapienza University, Viale del Policlinico, 155, Rome, 00161, Italy; Dr. Oliver Mann, MD, Senior Attending Physician and Deputy Director, Department of General, Visceral and Thoracic Surgery, University of Hamburg, Martini Str. 52, D-20246 Hamburg, Germany; Dr. Yuk Him Tam, Department of Surgery, Prince of Wales Hospital, Shatin, Hong Kong, China

Akaraviputh T, Arunakul S, Lohsiriwat V, Iramaneerat C, Trakarnsanga A. Surgery for gastrointestinal malignant melanoma: Experience from surgical training center. World J Gastroenterol 2010; 16(6): 745-748. Available from: URL: http://www.wjgnet.com/1007-9327/full/v16/i6/745.htm DOI: http://dx.doi.org/10.3748/wjg.v16.i6.745

INTRODUCTION

Malignant melanoma (MM) of the gastrointestinal (GI) tract is a rare condition, especially in Eastern countries. However, its incidence is rising with unclear reason[3]. It may be either primary or metastatic. GI metastasis of MM is frequently found during autopsy (50%-60% of cases), but a small proportion of melanoma patients are
diagnosed with GI metastasis while living (2%-5% of patients)\[2,3\]. The most common sites of the metastasis are the stomach and small intestine. Meanwhile, primary MM can arise in any GI mucosal site, but is most common in the anorectal region and esophagus.

The prognosis of GI MM is very poor with a 5-year survival of < 10%\[4\]. Surgery is still the mainstay of treatment. Recent studies have reported a trend toward less radical resection because there is no significant advantage of aggressive surgery over limited surgery in terms of local disease control, recurrence, and survival time\[5-8\].

In Thailand, MM is less common than in western countries and the data are limited. This study, therefore, was conducted to evaluate clinical features, surgical options, and outcome including recurrence and survival of MM of the GI tract in a surgical training center in Bangkok, Thailand.

**MATERIALS AND METHODS**

A retrospective review was conducted on patients diagnosed with MM of the GI tract who were admitted to Siriraj Hospital between 1997 and 2007. Patients were identified from the hospital computer database using an ICD-10 system. Patients’ charts were reviewed retrospectively for patient characteristics, presenting symptoms, physical examination findings, imaging results, operative records, presence of complications, recurrence, follow-up time, survival time, and cause of death. Diagnosis was confirmed in all patients by histological study and immunohistochemistry for S-100 protein or HMB45 monoclonal antibody. Survival time was defined as the number of months from the time of diagnosis of GI MM to the time of death or the last follow-up evaluation. The long-term follow-up data were collected by direct contact with patients or their relatives. A Kaplan-Meier method was used for statistical analysis of survival outcome. This study was approved by Siriraj ethics committee, Mahidol University (ECI 2550/307).

**RESULTS**

Between 1997 and 2007, there were 14 patients diagnosed with MM of the GI tract in Siriraj Hospital. One patient was excluded from this study due to insufficient data in the medical records; thus, only 13 cases were included in this study. Ten patients were female and three were male. The median age of the patients at presentation was 66 years (range: 32-87 years). Seven patients had a primary GI MM (anorectal, n = 5; sigmoid colon, n = 1; and stomach, n = 1), whereas the others (three patients, 23.1%) had metastatic MM of the GI tract. The primary melanoma sites of these three patients were ocular, thumb, and ovary. There were three patients who had advanced GI MM of unknown primary origin.

The most common presenting symptom was abdominal pain (5 patients, 38.5%), followed by intra-abdominal pain (5 patients, 38.5%), followed by intra-abdominal, thumb, and ovary. There were three patients who had metastatic MM of the GI tract. The primary GI MM was the most common site of GI MM (7 patients, 53.8%), followed by the stomach (3 patients, 23.1%) (Table 1).

Seven patients (53.8%) underwent curative resection, which consisted of three abdominoperineal resections, two wide local excisions, one total gastrectomy, and one sigmoidectomy. There was no perioperative mortality in this study. Meanwhile, another six patients (46.2%) had distant metastatic lesions at the time of diagnosis. They therefore received only palliative surgical treatment such as colostomy, small bowel resection, and enterostomy anastomosis. Patients who underwent curative resection exhibited a longer mean survival time (29.7 mo, range: 10-96 mo) than patients in the palliative group (4.8 mo, range: 4-12 mo) (Figure 1). Survival was significantly increased in patients who underwent curative resection (P = 0.0006).

**DISCUSSION**

In Thailand, MM is a rare disease. The estimated incidence rate of cutaneous melanoma in Thailand is 0.4 and 0.1 per 100000 in men and women, respectively\[9\]. Incidence of MM of the GI tract is exceedingly rare\[9\]. There have

**Table 1 Characteristic of patients with MM of the GI tract**

|                     | Curative group | Palliative group | All   |
|---------------------|----------------|-----------------|-------|
| n                   | 7              | 6               | 13    |
| Median age (yr)     | 66 (32-87)     | 57 (42-78)      | 66 (32-87) |
| Gender (M/F)        | 2/5            | 1/5             | 3/10  |
| Presenting symptoms |                |                 |       |
| Abdominal pain      | 1              | 4               | 5 (38.5) |
| Intra-abdominal mass| 4              | 0               | 4 (30.8) |
| Obstructive jaundice| 0              | 1               | 2 (15.4) |
| Small bowel obstruction| 0           | 1               | 1 (7.7)  |
| Bowel habit change  | 1              | 0               | 1 (7.7)  |
| Tenesmus            | 1              | 0               | 1 (7.7)  |
| Investigation n (%) |                |                 |       |
| Abdominal CT        | 5              | 3               | 8 (61.5) |
| Endoscopy           | 1              | 1               | 2 (15.1) |
| Upper GI study      | 0              | 1               | 1 (7.7)  |
| Barium enema        | 1              | 0               | 1 (7.7)  |
| Origin of GI MM n (%)|             |                 |       |
| Primary             | 7              | 0               | 7 (53.8) |
| Secondary           | 0              | 3               | 3 (23.1) |
| Unknown primary     | 0              | 3               | 3 (23.1) |
| Site of the tumor n (%)|            |                 |       |
| Anorectal           | 5              | 2               | 7 (53.8) |
| Stomach             | 1              | 2               | 3 (23.1) |
| Jejunum             | 0              | 1               | 1 (7.7)  |
| Pancreas            | 0              | 1               | 1 (7.7)  |
| Sigmoid colon       | 1              | 0               | 1 (7.7)  |
| Survival times (mo) | Mean           | 29.7            | 4.8   |
|                     | Range          | 10-96           | 4-12  |

MM: Malignant melanoma; GI: Gastrointestinal; CT: Computed tomography.
been only a few reported cases of documented anorectal MM in Thailand\[7\]. MM of the GI tract can be either primary or metastatic. Primary GI melanoma must be differentiated from metastatic disease by previous history of melanoma and complete physical examination.

Patients often present with bleeding, pain or intestinal obstruction. If the patients present with GI bleeding, an endoscopy with magnification might be the procedure of choice to diagnose MM of the GI tract\[8,9\]. Multiple black, depressed lesions (1 ± 5 mm in diameter) with a “bull’s eye” appearance are usually viewed in the GI mucosa\[9]. In the present study, approximately half of the patients presented with pain. A lower number of patients presented with gross GI bleeding and obstruction.

MM of the GI tract remains a fatal disease. Patients often present with advanced disease. In our study, almost half of the patients had metastatic disease at the time of presentation. The prognosis of GI MM is poor. The mean survival time of patients with a local or locoregional disease who underwent curative resection was only 29.7 mo. Several investigators have reported that the overall survival varies from 12 to 18 mo, with a 5-year survival of <10%\[9\]. When systemic metastasis has occurred, mean survival is only 6-8 mo\[12,13\].

As a result of the poor prognosis of this disease, operative intervention has been discouraged. However, several recent studies have demonstrated better survival outcome in the patients who had complete surgical resection\[14-19\]. Our experiences compare favorably with those of other centers. Our study demonstrated seven patients with GI MM who underwent curative resection with a mean survival comparable to that in other centers. Several adjuvant treatment of GI MM such as chemotherapy, radiotherapy and immunotherapy have been utilized in many countries, but no such treatment was given in our center because of their unclear effectiveness. One recent randomized trial has demonstrated no survival benefit of adjuvant therapy\[19\].

In conclusion, patients with GI MM had a poor prognosis, especially in nonoperable cases. Surgical resection of the tumor resulted in a longer survival time. In selected patients with local or locally advanced disease, surgery should be performed wherever possible.

**COMMENTS**

**Background**
Gastrointestinal (GI) malignant melanoma (MM) is a rare malignancy. As a result of the paucity of cases, the available data about its clinical features, treatment options, and outcomes are very limited, especially in Eastern countries.

**Research frontiers**
As a result of the poor prognosis of GI MM, improvement of its treatment options is an area that is in need of research. However, in order to reach that point, some basic understanding of the clinical characteristics and treatment outcomes of current surgical approaches is required. This study provides a picture of clinical experience with this rare disease from one surgical training center in Thailand.

**Innovations and breakthroughs**
This study revealed that the nature of MM of the GI tract and its treatment outcomes in Thailand were similar and comparable to those from other centers.

**Applications**
With a better understanding of GI MM and its poor prognosis, future research should look at how to improve the treatment outcome, through early diagnosis, selection of patients undergoing surgery, and improvement of surgical techniques.

**Peer review**
This is a retrospective study on surgical management of MM of the GI tract. Patients who underwent curative resection exhibited a longer mean survival time than patients in the palliative group. Survival was significantly increased in patients who underwent curative resection.

**REFERENCES**

1. **Klaase JM**, Kroon BB. Surgery for melanoma metastatic to the gastrointestinal tract. *Br J Surg* 1990; 77: 60-61
2. **Dasgupta T**, Brassfield R. Metastatic melanoma. A clinicopathological study. *Cancer* 1964; 17: 1323-1339
3. **Cagir B**, Whiteford MH, Topham A, Rakinic J, Fry RD. Changing epidemiology of anorectal melanoma. *Dis Colon Rectum* 1999; 42: 1203-1208
4. **Bullard KM**, Tuttle TM, Rothenberger DA, Madoff RD, Baxter NN, Finne CO, Spencer MP. Surgical therapy for anorectal melanoma. *J Am Coll Surg* 2003; 196: 206-211
5. **Promatatvethi V**, Gojisoni P, Buri P, Censarn N. Malignant melanoma: a clinical experience in a Thai hospital. *J Med Assoc Thai* 1978; 61: 210-216
6. **Crombie IK**. Racial differences in melanoma incidence. *Br J Cancer* 1979; 40: 185-193
7. **Somran J**, Kannugum S, Porncharoenpong S, Lertkajornsin O. Anorectal malignant melanoma: report of two cases from Buddhachinnaraj Hospital. *J Med Assoc Thai* 2005; 88: 1128-1133
8. **Pommer B**, Probst A, Messmann H. Gastric metastases from malignant melanoma. *Endoscopy* 2008; 40 Suppl 2: E30-E31
9. **Tanaka K**, Toyoda H, Hamada Y, Aoki M, Kosaka R, Noda T, Katsurahara M, Nakamura M, Ninomiya K, Inoue H, Imoto I. Duodenal metastasis of malignant melanoma observed by magnification endoscopy. *Endoscopy* 2008; 40 Suppl 2: E6-E7
10. **Galloro G**, Inzirillo A, Magni L, Diamantis G, Inzirillo M, Pastore A, Ruggiero S, Mosella G. Multiple nodular lesions by colonic metastatic malignant melanoma. *Dig Liver Dis* 2009; 41: 169
11. **Yang JI**, Byun HJ, Kang JM. Education and imaging. Gastrointestinal: anorectal malignant melanoma. *J Gastroenterol Hepatol* 2009; 24: 697
12. **Liang KV**, Sanderson SO, Nowakowski GS, Arora AS.
Metastatic malignant melanoma of the gastrointestinal tract. *Mayo Clin Proc* 2006; 81: 511-516

13 **Lens M**, Bataille V, Krivokapic Z. Melanoma of the small intestine. *Lancet Oncol* 2009; 10: 516-521

14 **Berger AC**, Buell JF, Venzon D, Baker AR, Libutti SK. Management of symptomatic malignant melanoma of the gastrointestinal tract. *Ann Surg Oncol* 1999; 6: 155-160

15 **Agrawal S**, Yao TJ, Coit DG. Surgery for melanoma metastatic to the gastrointestinal tract. *Ann Surg Oncol* 1999; 6: 336-344

16 **Ishizone S**, Koide N, Karasawa F, Akita N, Muranaka F, Ubara H, Miyagawa S. Surgical treatment for anorectal malignant melanoma: report of five cases and review of 79 Japanese cases. *Int J Colorectal Dis* 2008; 23: 1257-1262

17 **Sanki A**, Scolyer RA, Thompson JF. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. *Eur J Surg Oncol* 2009; 35: 313-319

18 **Huang YJ**, Wu MH, Lin MT. Multiple small-bowel intussusceptions caused by metastatic malignant melanoma. *Am J Surg* 2008; 196: e1-e2

19 **Slaby J**, Suri U. Metastatic melanoma with multiple small bowel intussusceptions. *Clin Nucl Med* 2009; 34: 483-485

20 **Spitler LE**, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, Soong SJ. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. *J Clin Oncol* 2000; 18: 1614-1621